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Abstract
Particle-based delivery systems are a promising approach to enhance antigen-specific
immunity for use in vaccines. Chitosan, a natural polysaccharide derived from the
exoskeletons of crustaceans, shows great potential as a vaccine carrier due to its favorable
properties as a biomaterial, including biocompatibility and biodegradability. In this study, the
intracellular uptake of chitosan nanoparticles is explored and compared to that of other
commonly used particle-based delivery vehicles, such as poly (lactic-co-glycolic acid)
(PLGA). Fluorescein isothiocyanate-labeled bovine serum albumin (FITC-BSA) was used as
a model protein antigen and encapsulated in both chitosan particles via precipitationcoacervation and PLGA particles via double emulsion solvent evaporation. Fluorescence
microscopy images showed that, when co-incubated with dendritic cells, all cells were found
to internalize FITC-BSA-chitosan nanoparticles. Additionally, punctate fluorescence in the
cytoplasm indicated that at least some of the particles were within endosomes at early (less
than 24 hour) time points. Furthermore, flow cytometry results showed chitosan particles to
have a greater uptake (74%) by dendritic cells compared to PLGA particles (32%) or soluble
protein (43%) at early time points (1 hour).
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1. Introduction
Vaccines play a vital role in modern medicine. While vaccines have been responsible for
the near elimination of some major diseases, such as smallpox and poliomyelitis, as well as
significant control over many other illnesses, there remain several diseases that require new and
improved vaccine formulations to enhance current treatments [1]. Presently, vaccine
development studies focus on using subunit antigens to elicit an immune response, which is a
safer but less effective method than delivering whole pathogens. Subunit antigens are rapidly
degraded by proteases upon injection. Furthermore, subunit antigens lack the requisite
immunostimulatory signals required for a robust adaptive immune response [2]. A delivery
system, therefore, is needed to increase the persistence of antigens and enhance the immune
response. Particle-based delivery systems in which antigens are encapsulated in polymeric nanoor microparticles are a promising approach and under intense investigation.
Several advantages of antigen encapsulation by nano- and/or micro particles have been
established. For one, encapsulation prevents antigen degradation. Two, polymeric particles can
be engineered to certain specifications, such as amount of adjuvant loading. Finally, antigenpresenting cells (APC) like macrophages and dendritic cells (DCs) phagocytize and process the
antigen-containing particles [2]. These properties demonstrate the potential of particle-based
vaccine delivery systems to enhance antigen-specific immunity.
The most commonly used material for particle-based delivery is poly (lactic-co-glycolic
acid) (PLGA), but another polymer, chitosan, shows great potential as a vaccine carrier.
Chitosan, a natural polysaccharide derived from the exoskeletons of crustaceans, has recently
been introduced in several biomedical applications due to its favorable properties and versatility
as a biomaterial, including biocompatibility and biodegradability. Chitosan is mucoadhesive,
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which has led to its exploration as a nasal and oral vaccine carrier. In addition, chitosan is highly
hydrophilic and positively charged, indicating its high protein loading capacity [1, 2]. Thus, this
remarkable natural polymer has shown great potential as a particle-based vaccine delivery
system, and may have advantages over PLGA.
Previous research in our lab, the Laboratory of Vaccine and Immunotherapy Delivery at
the University of Arkansas, has demonstrated that chitosan’s properties support its potential as an
effective vaccine carrier. Chitosan particles efficiently deliver encapsulated antigens and enhance
the activation of both macrophages and DCs [2]. Furthermore, antigen-encapsulated chitosan
particles outperformed soluble antigens in eliciting both humoral and cell-mediated antigenspecific immune responses [2].
To supplement these findings, my research focused on characterizing the uptake of
chitosan nanoparticle-based vaccines and comparing the uptake to other nanoparticles commonly
used in particle-based vaccine delivery, such as PLGA. Fluorescence microscopy was used to
determine the time course of internalization of nanoparticles by DCs. Flow cytometry was then
used to further quantify uptake. Cytotoxicity became of interest in the study, so cell viability
assays were performed and PI stain was used with flow cytometry as a measure of cell viability.
Finally, scanning electron microscopy (SEM) images were taken of both chitosan particles and
PLGA particles in the interest of comparing their morphologies. Fluorescein isothiocyanatelabeled bovine serum albumin (FITC-BSA) was used as a model protein antigen and
encapsulated in both chitosan particles via precipitation-coacervation and PLGA particles via
double emulsion solvent evaporation.
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2. Materials and Methods
2.1 Cell Culture
A murine immature dendritic cell line, JAWS II cells, were cultured in complete media
consisting of DMEM supplemented with 20% FBS, 1% penicillin/streptomycin, 1% Lglutamine, and 5ng/ml GM-CSF.

2.2 Particle synthesis
Chitosan particles encapsulating FITC-BSA were prepared via precipitation-coacervation
using low molecular weight chitosan [Batch #: MKBD0020, 448869-50G, CAS 9012-76-4]. For
full protocol, see appendix A. PLGA particles encapsulating FITC-BSA were prepared via
double emulsion solvent evaporation using PLGA (50/50). For full protocol, see appendix B.
Particles were lyophilized before further use. Particle size was measured via dynamic light
scattering (DLS) (Nano ZS90, Malvern Instruments, Malvern, UK).

2.3 Fluorescence Microscopy
Phase contrast images and fluorescence images were taken with a Nikon eclipse Ti
fluorescence microscope. Prior to imaging, cells were seeded in a 6-well plate at 2 million cells
per well and incubated overnight. Particle suspensions, chitosan or PLGA at 200 µg/ml, or FITCBSA solution at 20 µg/ml, were then added to different wells. Cells alone was used as a negative
control. The plate was incubated for the desired period of time. The samples were washed three
times with phosphate buffered saline (PBS) prior to imaging.
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2.4 Flow Cytometry
Flow cytometry was used to quantify cell-by-cell uptake of particles or FITC-BSA.
Briefly, cells were plated 1 million cells per well in a 6-well plate. Chitosan or PLGA suspension
(200 µg/ml) or FITC-BSA solution (20 µg/ml) were added to appropriate wells. The plate was
incubated for the desired time, either 1 hour or 24 hours. Samples were harvested after the
incubation period and were washed and re-suspended in PBS prior to measuring. PI stain (2µl)
was added just before measuring.

2.5 Viability Assays
Two different viability assay kits were used: 1) CytoTox-Glo Cytotoxicity Assay (see
appendix C for product instructions) and 2) CellTiter-Glo Luminescent Cell Viability Assay (see
appendix D for product instructions). Briefly, JAWS II cells were seeded in a 96-white wall
plate. Particle suspensions or FITC-BSA solution was added to appropriate wells and the plate
was incubated for 1 hour or 24 hours. Plates were prepared for measurement after the incubation
period according to the respective assay protocol. Luminescence was read with a plate reader and
reported in relative light units (RLU).

2.6 Scanning Electron Microscopy
Lyophilized particles were sputter coated with gold prior to imaging. SEM images were
acquired at a beam voltage of 10-15 kV.
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3. Results and Discussion
Chitosan particles had a mean diameter size of 521.5nm ± 123.4 (n=18) and PLGA
particles had a mean diameter of 281.1nm ± 52.3 (n=4) as determined via dynamic light
scattering (DLS). Fluorescence images verified the successful encapsulation of fluorescein
isothiocyanate-labeled bovine serum albumin (FITC-BSA) by chitosan nanoparticles (Figure 1).

!
Figure 1. Chitosan nanoparticles encapsulating FITC-BSA (green). 40x.

The time course of internalization of chitosan particles by dendritic cells was
determined using fluorescence microscopy. When co-incubated with JAWS II cells, all cells
were found to internalize FITC-BSA-chitosan nanoparticles. Additionally, punctate fluorescence
in the cytoplasm indicated that at least some of the particles were within endosomes at early (~1
hour) time points (Figure 2). Cells alone showed no fluorescence, which was expected for the
negative control. Cells co-incubated with chitosan particles appear to have the highest intensity
of FITC fluorescence signal. Cells co-incubated with FITC-BSA or with PLGA particles showed
some fluorescence but less than that of cells with chitosan particles. This suggests that the
dendritic cells more readily took up chitosan particles than PLGA particles or soluble protein
antigens.

!

6!

A

C

B

D
!

Figure 2. Representative phase contrast images (left) and corresponding fluorescence (green) images (right)
of cells alone (A) or cells co-incubated with FITC-BSA (B), chitosan particles (C), or PLGA particles (D). 1hour incubation period. All images: 40x. Performed 3 times with similar results.

To quantify intracellular uptake, cell-by-cell analysis was performed using flow
cytometry. An increase in intensity, or right shift, in the FITC channel (P3) denotes an increase
in protein (FITC-BSA) or particle uptake. Likewise, an increase in intensity in the PE channel
(P2) denotes an increase in percentage of the population stained with propidium iodide (PI). PI
stain was included as a measure of cell viability.
It was found that intracellular uptake is greater with chitosan particles than PLGA
particles or FITC-BSA (Figure 3). After a 1-hour incubation period, cellular uptake of chitosan
was 74% compared to only 32% with PLGA and 43% with FITC-BSA. Uptake showed an
increase at 24 hours compared to 1 hour with both particles and FITC-BSA, but chitosan
particles retained the highest value, 77%, compared to 45% with PLGA and 59% with FITCBSA. These results, together with fluorescence microscopy images, support that chitosan
particles stimulate greater intracellular uptake than PLGA particles or soluble protein antigens.
The PE channel showed that cell viability appears to decrease more with chitosan
particles than PLGA particles after 24-hour incubation. At 1 hour, there was little decrease in cell
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viability with either particle. At 24 hours, however, cell viability had decreased by 31% with
chitosan particles and only 11% with PLGA particles. There were a few things to consider when
analyzing this result. First, since uptake of chitosan particles was significantly higher than that of
PLGA, the larger decrease in cell viability with chitosan particles may be due to a higher
concentration (dose) of particles rather than increased cytotoxicity. It is also important to note
that while the percentage values provide a good quantitative measure of the increase in signal
intensity, the visual shift in intensity provides the best comparison. In other words, it is difficult
to affirm that, for example, there was precisely a 31% decrease in cell viability at 24 hours of
cells co-incubated with chitosan particles. With this in mind, the shifts in the PE channel of cells
co-incubated with chitosan particles or PLGA particles at 24 hours are visually more similar than
the percentages suggest. The shift in the FITC channel, on the other hand, is obviously more
dramatic with chitosan particle uptake compared to PLGA particle uptake. Additionally, there
may be some interaction between chitosan and PI causing the shift in intensity. Repeat studies
are necessary to verify that PI and chitosan are not interacting.
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Figure 3. Flow cytometry of cells alone (A), cells co-incubated with FITC-BSA for 1 hour (B) or 24 hours (C),
cells co-incubated with chitosan particles for 1 hour (D) or 24 hours (E), and cells co-incubated with PLGA
particles for 1 hour (F) or 24 hours (G). P1 (left) is the selected population, P2 (middle) is a PE channel gate, and
P3 (right) is a FITC channel gate. The percentage in the top right corner of each image is the percent of the parent
population that corresponds to the selected region or positive channel signal. Performed 3 times (only once with PI
stain) with similar results.
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Viability assays were used to further investigate cytotoxicity of both polymeric particles.
Results with the CytoTox-Glo Cytotoxicity Assay showed that there was no significant decrease
in cell viability after 1 hour of incubation with either chitosan particles (P=0.158) or PLGA
particles (P=0.347) (Figure 4). After 24 hours of incubation, however, there was a significant
decrease in cell viability in cells co-incubated with PLGA particles (P=0.0047). There was not a
significant decrease in cell viability in cells co-incubated with chitosan particles (P=0.129)
(Figure 5).
Results with the CellTiter-Glo Luminescent Cell Viability Assay showed that as particle
concentration increases, viable cell luminescence decreases. There was a significant decrease in
cell viability with 25µg and 50µg of PLGA particles and with 50µg of chitosan particles (Figure
6). Table 1 shows the measured RLU values and Figure 7 shows the percent difference
calculations of cell viability as particle concentration increases between cells alone and cells coincubated with chitosan particles or between cells alone and cells co-incubated with PLGA
particles.
It appears that chitosan particles are less toxic than PLGA particles. It is noteworthy,
however, that particle concentrations in this study are relatively low, so results may vary at
higher concentrations. Also, results could not yet be reproduced, so further experimentation is
necessary to validate these results or draw more concrete conclusions.
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Figure 4. Viable cell luminescence. JAWS II cells were incubated alone or co-incubated with chitosan particles or
PLGA particles for 1 hour. Particle concentration was 200µg/ml. Bars indicate relative light units (RLU) as
determined by CytoTox-Glo Cytotoxicity Assay. (n=1)

!
Figure 5. Viable cell luminescence. JAWS II cells were incubated alone or co-incubated with chitosan particles or
PLGA particles for 24 hours. Particle concentration was 200µg/ml. Bars indicate relative light units (RLU) as
determined by CytoTox-Glo Cytotoxicity Assay. *p<0.05 compared to cells alone. (n=1)
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Table 1. Viable cell luminescence measured in relative light units (RLU) as determined by CellTiter-Glo
Luminescent Cell Viability Assay. Values were used in Figures 6 and 7.

!
Figure 6. Viable cell luminescence. JAWS II cells were incubated alone or co-incubated with either chitosan
particles or PLGA particles for 24 hours at increasing concentrations. Bars indicate relative light units (RLU) as
determined by CellTiter-Glo Luminescent Cell Viability Assay. *p<0.05 compared to cells alone. **p<0.01
compared to cells alone. Samples were plated in triplicate, so error bars represent standard deviation of three wells
of repeated samples in the same study. (n=1)
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Figure 7. Percent difference in cell viability in cells co-incubated with chitosan particles or PLGA particles
compared to cells alone at increasing amounts of particles. Calculated using values from Table 1.

Lastly, I investigated the morphology of chitosan particles and PLGA particles with
scanning electron microscopy (SEM). Representative SEM images are shown in Figure 6. The
images I acquired with PLGA did not match those found in literature, so I cannot be sure that the
chitosan images are accurate either. It may be that a different sample preparation method is
required to obtain better images.

A

B
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Figure 8. Representative SEM images of chitosan particles (A) and PLGA particles (B).
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There are several avenues of future research that could be pursued. For one, repeat
studies using the CellTiter-Glo Luminescent Cell Viability Assay kit need to be performed in
order to draw conclusions about the differences in cytotoxicity between chitosan particles and
PLGA particles. Moreover, repeat studies using PI stain with flow cytometry could be used to
support the viability assay results. It would be worthwhile to experiment with a higher and wider
range of particle concentrations, as well.
Furthermore, multiphoton microscopy would provide better, clearer images than the
fluorescence microscopy used in this study. Multiphoton images would show greater detail and
more qualitative information could probably be determined by analyzing the intracellular uptake
of particles more closely.
Additionally, performing flow cytometry with samples incubated for periods greater than
24 hours may be useful in determining intracellular retention rate of particles. This data could
indicate the time period between uptake by DCs and DC maturation and antigen presentation.
Another study to pursue is SEM imaging. Morphology of the particles may play a role in
their intracellular behavior, so knowledge of the differences in morphology between chitosan and
PLGA particles may be valuable in analyzing the differences in the cellular mechanisms of
uptake and processing of either particle.

4. Conclusions
In conclusion, dendritic cells internalized FITC-BSA-encapsulated chitosan nanoparticles
at early (~1 hour) time points. When co-incubated with JAWSII cells, all cells were found to
internalize FITC-BSA-chitosan nanoparticles. Punctate fluorescence in the cytoplasm indicated
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that at least some of the particles were within endosomes at early (less than 24 hour) time points.
Cellular uptake of particles appears to be greater with chitosan particles compared to
PLGA particles at early time points (1 hour). Intracellular uptake increased from 1 hour to 24
hours with both chitosan and PLGA particles, but chitosan particle uptake remained significantly
higher (77% compared to 45% with PLGA).
Additional data is required, but there may be a significant difference in cytotoxicity
between PLGA and chitosan particles. My results show that chitosan particles are somewhat less
toxic than PLGA particles after 24-hour incubation with cells.
Tunable release kinetics is a key advantage of polymeric nanoparticle delivery systems.
The increased uptake with chitosan particles compared to PLGA particles suggest chitosan
particles may provide greater sustained release of loaded molecules, and therefore could present
the greatest immunostimulatory response.
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Appendix A
Protocol: Chitosan Nanoparticles
(Bhanu, Wilson et al 2013)
1. Prepare 2% v/v acetic acid solution by adding 200 µl acetic acid in 9.8 ml of DI water
2. Add 10 mg chitosan (Sigma Low MW) to the acetic acid solution on a magnetic stirrer and
mix for 1 hour (~850 RPM).
3. Add 100 µl (or 1 mg) of FITC-BSA and mix for 10 min in the dark (~800 RPM)
4. Prepare 10% w/v sodium sulfate solution by adding 1 g sodium sulfate to 10 ml DI water and
mix
5. Use infusion pump to add 1 ml sodium sulfate solution to chitosan solution drop wise until
particle formation is observed
6. Add 50 mg Pluronic F-68 to the solution and stir for 5 min
7. Stir the nanoparticle solution for another 30 minutes while sonicating (30-40 W) every 15 min
for 60 sec to obtain better dispersion
8. Use the nanosizer to determine the size of the chitosan nanoparticles
•

1 ml DI water + 100 µl chitosan solution in cuvette

•

Remove any bubbles before measuring

9. Centrifuge at 15000 RPM for 8 min
10. Keep supernatant (wrap in foil and store in 4°C fridge to use in drug loading efficiency
calculations) and resuspend the pellet in ~10 ml DI water and sonicate for 1 min in water
bath sonicator
11. Centrifuge again at 15000 RPM for 8 min
12. Dispose of the supernatant and resuspend the pellet in 5 ml of DI water
13. Transfer the solution to a 15 ml conical tube, wrap in foil, and store in -80°C freezer

Appendix B
Protocol: PLGA nanoparticles (300nm)
(Bhanu et al, 07/14/13)
PLGA nanoparticles encapsulating OVA antigen were prepared using a double emulsion solvent
evaporation method.
Note: Make sure all the components used in the reactions including beakers, pipettes etc. are of
glass. Do not use plastic containers or pipettes to handle the solutions.
1. Prepare 12ml 2% w/v PLA solution by taing 240mg of PVA into 12ml DI water
2. Mix the solution at room temperature for 1 hour
3. Prepare protein solution by dissolving 2 mg of FITC-BSA in 200µl DI water (use black
eppindorf tube to protect from light)
4. Prepare 3% PLGA solution by dissolving 90mg of PLGA (50/50) in 3ml of
dichloromethane (DCM) in a 10ml beaker
5. Cover the beaker mouth tightly with aluminum foil
6. Mix the solution at 600 RPM for 10 – 15 minutes
7. After 15 minutes, increase the stirring speed of PLGA mixture to 800 RPM and slowly
add the protein solution drop wise
8. Transfer the mixture to an ice bath and sonicate at 40W for 30 seconds
9. Keep the PVA solution on the stirrer mixing at 800 RPM
10. Slowly add the PLGA mixture to PVA solution using a glass transfer pipette
11. Let the solution mix for 2 minutes
12. Transfer the beaker to an ice bath and sonicate the solution at 50W for 2 minutes
13. Transfer the beaker back to stirrer
14. Close the mouth of the beaker with aluminum foil

Appendix B
15. Poke 3-4 holes in the aluminum foil lid using a pipette tip
16. Leave the beaker on stirrer overnight to allow DCM to evaporate
17. After stirring overnight, transfer PLGA nanoparticles solution into centrifuge tubes
18. Weigh balance the centrifuge tube and centrifuge for 10 minutes at 20,000 RPM using
high speed centrifuge
19. Collect the supernatant – Can be used to determine the loading efficiency
20. Re-suspend the pellet in 10ml DI water – Make sure the particles are mixed well into the
solution
21. Centrifuge the particle solution for 10 minutes at 20,000 RPM using high speed
centrifuge
22. Discard the supernatant and re-suspend the protein loaded PLGA nanoparticles in 10ml
DI water
23. Mix well and freeze at -80°C before freeze drying
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Description

The CytoTox-Glo™ Cytotoxicity Assay(a,b) is a single-reagent-addition,
homogeneous, luminescent assay that allows measurement of the number of
dead cells in cell populations (Figure 1). The CytoTox-Glo™ Assay shows
excellent correlation with other methods of assessing cell viability (Figure 2).
The CytoTox-Glo™ Assay measures a distinct protease activity associated with
cytotoxicity (1). The assay uses a luminogenic peptide substrate (alanyl-alanylphenylalanyl-aminoluciferin; AAF-Glo™ Substrate) to measure “dead-cell
protease activity”, which is released from cells that have lost membrane integrity
(Figure 3). The AAF-Glo™ Substrate cannot cross the intact membrane of live
cells and does not generate any appreciable signal from the live-cell population.
The assay selectively detects dead cells (Figure 4). The CytoTox-Glo™ Assay
relies on the properties of a proprietary thermostable luciferase (Ultra-Glo™
Recombinant Luciferase), which uses aminoluciferin as a substrate to generate a
stable "glow-type" luminescent signal and is formulated to improve
performance across a wide range of assay conditions.
With the addition of Lysis Reagent (provided), the CytoTox-Glo™ Cytotoxicity
Assay also can deliver the luminescent signal associated with the total number
of cells in each assay well. Viability can be calculated by subtracting the
luminescent signal resulting from experimental cell death from total
luminescent values (Section 5).
Promega Corporation · 2800 Woods Hollow Road · Madison, WI 53711-5399 USA
Toll Free in USA 800-356-9526 · Phone 608-274-4330 · Fax 608-277-2516 · www.promega.com
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Step 1. Measure dead-cell number.

AAF-Glo™
Substrate

Assay
Buffer

AAF-Glo™ Reagent
(4X reagent)

Add AAF-Glo™ Reagent. Mix.
Incubate for 15 minutes at
room temperature.

Measure luminescence
to determine number of
dead cells.

Step 2. Measure total cytotoxicity (optional).

Assay Buffer

Digitonin

Lysis Reagent

Add Lysis Reagent. Mix.
Incubate for 15 minutes
at room temperature.

6202MA

Measure luminescence
to determine total
cell number.

Total Cell Number – Dead-Cell Number = Viable Cell Number

Figure 1. Schematic diagram of the CytoTox-Glo™ Cytotoxicity Assay.
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Assay Advantages
Measure the Relative Number of Dead Cells in Culture: Measure cytotoxicity
by adding a single reagent with the homogeneous “add-mix-measure” protocol.
Normalize Data for Cytotoxicity: Data normalization for dead-cell number
makes results more comparable well-to-well, plate-to-plate and day-to-day.
Measure the Relative Number of Remaining Viable Cells Using a Total Lysis
Protocol: Correlate increased cytotoxicity with a reduction in viable cells.
Improve Your Data: Reduce statistical probability of false positives (or negatives),
and eliminate fluorescence interference issues with a stable luminescence readout.
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Figure 2. The CytoTox-Glo™ Cytotoxicity Assay shows strong correlation with
established methods for measuring cytotoxicity. Panel A. The CytoTox-Glo™
Cytotoxicity Assay signal from serial twofold dilutions of dead cells plotted against
results from the CytoTox-ONE™ Homogeneous Membrane Integrity Assay, which
measures LDH release. Panel B. The CytoTox-Glo™ Assay signal from serial
dilutions of dead cells plotted against results achieved using ethidium homodimer
(DNA quantitation).
Promega Corporation · 2800 Woods Hollow Road · Madison, WI 53711-5399 USA
Toll Free in USA 800-356-9526 · Phone 608-274-4330 · Fax 608-277-2516 · www.promega.com
Printed in USA.
Revised 2/15

Part# TB359
Page 3

-

H
AAF-N

S

N

N

S

COOH

Dead-cell
protease activity
H2N
AAF- +

S

N

N

S

COOH
+ ATP + O2

Luciferase
Mg2+

6393MA

Light

Figure 3. Cleavage of the luminogenic AAF-Glo™ Substrate by dead-cell protease
activity. Following cleavage, a substrate for luciferase (aminoluciferin) is released,
resulting in the luciferase-mediated production of light.
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Figure 4. The CytoTox-Glo™ Cytotoxicity Assay signal derived from lysed cells
is extremely sensitive and proportional to cell number and demonstrates selective
detection of dead cells.
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2.

Product Components and Storage Conditions

Product
CytoTox-Glo™ Cytotoxicity Assay

Size
10ml

Cat.#
G9290

G9290 contains sufficient reagents for 100 assays at 100µl per assay in a 96-well plate
format or 400 assays at 25µl per assay in a 384-well plate format. Includes:

• 1 bottle
• 2 × 5ml
• 1 × 40µl

AAF-Glo™ Substrate
Assay Buffer
Digitonin

Product
CytoTox-Glo™ Cytotoxicity Assay

Size
5 × 10ml

Cat.#
G9291

G9291 contains sufficient reagents for 500 assays at 100µl per assay in a 96-well plate
format or 2,000 assays at 25µl per well in a 384-well format. Includes:

• 5 bottles
• 10 × 5ml
• 1 × 175µl

AAF-Glo™ Substrate
Assay Buffer
Digitonin

Product
CytoTox-Glo™ Cytotoxicity Assay

Size
2 × 50ml

Cat.#
G9292

G9292 contains sufficient reagents for 1,000 assays at 100µl per assay in a 96-well plate
format or 4,000 assays at 25µl per well in a 384-well format. Includes:

• 2 bottles
• 4 × 25ml
• 2 × 175µl

AAF-Glo™ Substrate
Assay Buffer
Digitonin

Storage Conditions: Store the CytoTox-Glo™ Cytotoxicity Assay components
at –20°C, protected from light. See product label for expiration date information.
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3.

Reagent Preparation and Storage

1.

Thaw the CytoTox-Glo™ Cytotoxicity Assay components in a 37°C water bath.
Mix the components to ensure homogeneity.

2.

Prepare the CytoTox-Glo™ Cytotoxicity Assay Reagent by transferring the
contents of one bottle of Assay Buffer to the AAF-Glo™ Substrate bottle.
Note: The appearance of the AAF-Glo™ Substrate prior to addition of Assay
Buffer may vary from lot to lot. This variation does not affect assay
performance.

3.

Prepare the Lysis Reagent one of two ways, depending on the protocol used.
a.

For Section 4.A, transfer Assay Buffer (2.75ml for Cat.# G9290 and
G9291; 13.75ml for Cat. G9292) to a conical tube. Prepare Lysis Reagent
by transferring Digitonin (13µl for Cat.# G9290 and G9291; 65µl for Cat.
G9292) to the conical tube containing Assay Buffer. Mix to ensure
homogeneity.

b.

For Sections 4.B and 4.C, transfer Digitonin (33µl for Cat.# G9290 and
G9291; 162µl for Cat.# G9292) to the Assay Buffer (5ml for Cat.# G9290
and G9291; 25ml for Cat.# G9292). Mix well to ensure homogeneity.
Note: Because the Lysis Reagent can be added before or after the
CytoTox-Glo Cytotoxicity Assay Reagent, the volume of digitonin added
to Assay Buffer differs. The difference in the volume of cells means that
the volume of digitonin has to be adjusted to be delivered at the same
lytic concentration.

Storage: For optimal results, use freshly prepared CytoTox-Glo™ Cytotoxicity
Assay Reagent (rehydrated AAF-Glo™ Substrate). Use within 12 hours if stored
at room temperature. The CytoTox-Glo™ Cytotoxicity Assay Reagent and Lysis
Reagent can be stored at 4°C for up to 7 days with no appreciable loss of
performance. The CytoTox-Glo™ Cytotoxicity Assay Reagent may be stored in
single-use aliquots for up to 4 months at –70°C. Freezing and thawing will
damage the reagent and must be avoided.
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4.

Protocols

Materials to be Supplied by the User
• 96-, 384- or 1536-well, white-walled tissue culture plates compatible with
luminometer and fluorometer (clear or solid bottom)
• multichannel pipettor or liquid-dispensing robot
• reagent reservoirs
• luminescence plate reader or multimode reader
• orbital plate shaker
• positive control cytotoxic compound
If you have not performed this assay with your cell line previously, we strongly
recommend that you determine the assay sensitivity for your cells using one of
the two methods described below (Section 4.A or 4.B). Use Method 1 to
determine the linear range of the assay for your cell type. Use Method 2 to
determine the practical sensitivity once you have already chosen the number of
cells to use in the assay. If you do not need to determine assay sensitivity for
your cells, proceed to Section 4.C.
4.A. Determining Assay Sensitivity, Method 1
In this method, the Lysis Reagent is added as the first reagent to simulate
experimental cytotoxicity. Lysis Reagent is added as the first reagent to effect
100% cytotoxicity in the presence of a limited number of cells to determine
assay sensitivity. The luminescence measured reflects total cell luminescence.
In all other assay applications, Lysis Reagent is added after the CytoTox-Glo™
Reagent. CytoTox-Glo™ Reagent is first added, and luminescence is measured
to determine dead cell luminescence. Lysis Reagent is then added, and
luminescence is measured to determine total cell luminescence. The final
concentration of the Lysis Reagent used in this method is different than that
when Lysis Reagent is added after the CytoTox-Glo™ Reagent. These two
concentrations of Lysis Reagent cannot be used interchangeably.
1. Harvest adherent cells (by trypsinization, etc.), wash with fresh medium to
remove residual trypsin and resuspend in fresh medium.
Note: For cells growing in suspension, proceed to Step 2.
2. Determine the number of viable cells by trypan blue exclusion using a
hemacytometer, and then dilute to 100,000 viable cells/ml in at least 3.0ml
of fresh medium.
Note: Concentrate cells by centrifugation if the cell suspension is less dense
than 100,000 cells/ml.
3. Add 100µl of the 100,000 cell/ml suspension (10,000 cells/well) to all wells
of row A and B in a 96-well plate.
4. Add 100µl of fresh medium to all wells in rows B–H.
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4.A. Determining Assay Sensitivity, Method 1 (continued)
5. Using a multichannel pipettor, mix the cell suspension in row B by
pipetting, being careful not to create foam or bubbles. Transfer 100µl from
each well of row B to row C. Repeat mixing, and transfer 100µl from row C
to row D. Continue this process to row G. After mixing the diluted
suspension in row G, aspirate 100µl from the wells, and discard. This
procedure creates dilutions of 10,000 cells/well in row A to 156 cells/well
in row G. Row H will serve as the no-cell background control (Table 1).

Table 1. Schematic Diagram of 96-Well Plate Layout.
2

3

4

5

6

7

8

A

10,000 Cells/Well

B

5,000 Cells/Well

C

2,500 Cells/Well

D

1,250 Cells/Well

E

625 Cells/Well

F

313 Cells/Well

G

156 Cells/Well

H

0 Cells/Well
untreated

9

10 11 12

6395MA

1

treated

6. Prepare Lysis Reagent according to instructions in Section 3, Step 3.a.
7. Using a multichannel pipettor, add 50µl of Lysis Reagent to all wells of
columns 7–12 to lyse cells; these are the treated samples. Add 50µl of the
remaining Assay Buffer to all wells in columns 1–6 so that all wells have
equal volumes; these are the untreated samples. Mix by orbital shaking at
700–900rpm for at least 1 minute.
8. Prepare the CytoTox-Glo™ Cytotoxicity Assay Reagent as described in
Section 3, and add 50µl to each well. Mix briefly by orbital shaking, and
incubate at room temperature for 15 minutes.
Note: Maximal sensitivity is achieved within 15 minutes. The signal intensity
will remain largely unchanged for approximately 30 minutes to 1 hour,
depending on plate-well density. The signal half-life is approximately
5 hours in a 96-well plate but shorter (about 2 hours) in a 1536-well plate.
9. Measure luminescence.
Note: You may need to adjust instrument gain setting (applied
photomultiplier tube energy).
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10. Calculate the signal-to-noise (S:N) ratios to determine practical sensitivity for
your cell type for each dilution of cells (10,000 cells/well; 5,000 cells/well, etc.).
Cytotoxicity S:N =

(Average Treated RLU – Average Untreated RLU)
S.D. of No-cell Background Controls (H1 through H6)

Note: The practical level of assay sensitivity for either assay is a signal-tonoise ratio of greater than 3 standard deviations (derived from reference 2).
4.B. Determining Assay Sensitivity, Method 2
1. Harvest adherent cells (by trypsinization, etc.), wash with fresh medium to
remove residual trypsin and resuspend in fresh medium.
Note: For cells growing in suspension, proceed to Step 2.
2. Determine the number of viable cells by trypan blue exclusion using a
hemacytometer, then dilute to 100,000 viable cells/ml in at least 20ml of
fresh medium.
Note: Concentrate the cells by centrifugation if the cell suspension is less
dense than 100,000 cells/ml.
3. Divide the volume of diluted cells into two separate tubes. Subject one tube
to “moderate” sonication, which is empirically determined by post-sonication
morphological examination, to disrupt cell membrane integrity and to
simulate a 100% population of dead cells. The second tube of untreated
cells will serve as the maximum viable population.
4. Create a spectrum of viability by blending sonicated and untreated
populations in 1.5ml tubes as described in Table 2.
Table 2. Spectrum of Viability Generated by Blending Sonicated and
Untreated Cells.
Percent Viability

Volume of Sonicated
Cells (µl)

Volume of Untreated
cells (µl)

100
95
90
75
50
25
10
5
0

0
50
100
250
500
750
900
950
1,000

1,000
950
900
750
500
250
100
50
0
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4.B. Determining Assay Sensitivity, Method 2 (continued)
5. After mixing each blend of sonicated and untreated cells by gentle
vortexing, pipet 100µl of each blend into eight replicate wells of a 96-well
plate. Add the 100% viable cell sample to column 1, 95% viable to column 2,
etc. Add 100µl of cell culture medium only to column 10 to serve as the
no-cell background control.
6. Add 50µl of CytoTox-Glo™ Cytotoxicity Assay Reagent to all wells, mix
briefly by orbital shaking and then incubate for 15 minutes at room
temperature.
Note: Maximal sensitivity is achieved within 15 minutes. The signal intensity
will remain largely unchanged for approximately 30 minutes to 1 hour,
depending on plate-well density. The signal half-life is approximately
5 hours in a 96-well plate but shorter (about 2 hours) in a 1536-well plate.
7. Measure luminescence.
Total Cell Number (optional)
8. Add 50µl of Lysis Reagent prepared according to instructions in Section 3,
Step 3.b. Mix by orbital shaking, and then incubate at room temperature for
15 minutes.
9. Measure luminescence.
10. Calculate the signal-to-noise (S:N) ratios to determine practical sensitivity
for your cell type for each blend of cell viability (X = 95%, 90%, etc.).
Note: The practical level of assay sensitivity for either assay is a signal-tonoise ratio of greater than 3 standard deviations (derived from reference 2).

Cytotoxicity S:N =

Viability S:N =

Average luminescence
–
for X%

Average luminescence
for 100% viable cells

S.D. of 100% viable cells
Average total
luminescence for X%

–

Average luminescence
for 0% viable cells

S.D. of 0% viable cell sample

4.C. Example Cytotoxicity Assay Protocol and Viability (by Lysis) Assay Protocol
Representative data are shown in Figure 5.
1. Set up 96-well assay plates containing cells in culture medium at the
desired density.
2. Add test compounds and vehicle controls to appropriate wells so that the
final volume is 100µl in each well (25µl for a 384-well plate).
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150,000

150,000

100,000

100,000
50,000

50,000
0
-8

-7

-6

-5

-4

0

log10 Calcium ionophore concentration (M)

6552MA

Live Cell Luminescence (RLU)

200,000

Dead Cell Luminescence (RLU)

AAF-Glo™ Substrate (Live) EC50 = 3.9µM
AAF-Glo™ Substrate (Dead) EC50 = 4.1µM

Figure 5. Determining cytotoxicity and viability by lysis. Calcium ionophore was
serially diluted twofold from 100µM in RPMI 1640 medium with 10% FBS in 50µl
volumes. Jurkat cells were added at 10,000 cells/well in a 50µl volume. The plate
was shaken briefly using an orbital shaker and then incubated for 6 hours at 37°C in
5% CO2. The CytoTox-Glo™ Cytotoxicity Assay Reagent was prepared, and 50µl was
added to each well. After another brief mix, the plate was incubated at room
temperature for 15 minutes and the dead cell signal measured using a BMG
POLARStar luminometer. The Lysis Reagent was prepared, and 50µl was added to
each well to achieve complete cell lysis. Luminescence was measured after
15 minutes of incubation at room temperature. The luminescent signal collected
after lysis was adjusted to reflect the “live cell” contribution by subtracting the
initial dead cell signal. The data above are plotted as “dead cell” or “live cell” signal
versus the concentration of calcium ionophore.
3. Culture cells for the desired test exposure period.
Note: All enzymatic markers for cytotoxicity have finite activity half-lives
(Figure 6). Although the protease marker(s) measured in this assay
demonstrate an improved stability profile compared to other enzymatic
markers under most circumstances, we recommend exposing the cells to
the test compound for 24 hours or less to ensure that cytotoxicity is not
underestimated. If longer exposures are desired, reducing the initial
compound concentration may influence the kinetics of cytotoxicity and
benefit the assessment of cell death.
4. Add 50µl of CytoTox-Glo™ Cytotoxicity Assay Reagent to all wells
(12.5µl for a 384-well plate). Mix briefly by orbital shaking, and incubate for
15 minutes at room temperature.
Note: Maximal sensitivity will be achieved within 15 minutes. The signal
intensity will remain largely unchanged for approximately 1 hour. The
signal half-life is approximately 5 hours.

Promega Corporation · 2800 Woods Hollow Road · Madison, WI 53711-5399 USA
Toll Free in USA 800-356-9526 · Phone 608-274-4330 · Fax 608-277-2516 · www.promega.com
Printed in USA.
Revised 2/15

Part# TB359
Page 11

4.C. Example Cytotoxicity Assay Protocol and Viability (by Lysis) Assay Protocol
(continued)
5. Measure luminescence.
6. Add 50µl of Lysis Reagent (prepared according to instructions in Section 3,
Step 3.b) to all wells (12.5µl for a 384-well plate). Mix, and incubate at room
temperature for 15 minutes.
7. Measure luminescence.
8. Calculate the luminescent contribution of previously viable cells (after
lysis) by subtracting the luminescent signal resulting from experimental
cell death (Step 5) from total luminescence death (Step 7).
Viable cell luminescence = Total luminescence – Experimental dead cell
luminescence
Glyceraldehyde-3-phosphate dehydrogenase (luminesence)
Adenylate kinase (luminesence)
Dead-cell protease (luminesence)
Lactate dehydrogenase (fluorescence)

100

% Activity

75

50

0

0

2

4

6

Hours after Cytotoxic Event

8

10

6689MA

25

Figure 6. Half-life of enzymatic markers for cytotoxicity. Jurkat cells were plated
in white-walled plates in 100µl at a density of 10,000 cells per well in RPMI 1640
medium + 10%FBS. Digitonin was added to appropriate replicate wells in 10µl
(30µg/ml final concentration) every hour for 10 hours to facilitate maximal
cytotoxicity. The plate was incubated at 37°C during this period. CytoTox-Glo™
Reagent and reagents to measure glyceraldehyde-3-phosphate dehydrogenase and
adenylate kinase activities were prepared and added as directed by the manufacturer.
Luminescence was measured after 15 minutes using a BMG POLARstar luminometer.
CytoTox-ONE™ Reagent was prepared and added as directed. Fluorescence was
measured using a Labsystems Fluoroskan Ascent plate reader. All data were
background-subtracted and plotted as a percentage of the last lysis time point.
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4.D. Recommended Controls
No-Cell Background Control: Prepare triplicate wells without cells to serve as
the negative control to determine background signal.
Untreated Cells Control: Prepare triplicate wells with untreated cells to serve
as a vehicle control. Add the same solvent used to deliver the test compounds
to the untreated-cells control wells.
Test Compound Control: Prepare triplicate wells without cells and containing
the vehicle and test compound to test for possible interference with the
CytoTox-Glo™ Assay chemistry.
Positive Control for Cytotoxicity: Prepare triplicate wells containing cells
treated with a compound known to be toxic to the cells used in your model
system (staurosporine, ionomycin, etc.).

5.

General Considerations

Assay Principle
The CytoTox-Glo™ Assay detects both the dead and live cell populations found
in a sample using sequential luminescent measures. Data are collected as
relative light units (RLU). The CytoTox-Glo™ Assay achieves a signal steadystate between the dead-cell protease and firefly luciferase from 2,500 dead cells
after about 15 minutes. The same number of live cells in the control well
contribute a small, but measurable, background signal. After addition of
digitonin to lyse remaining viable cells, a new steady-state signal is reached
that represents a proportional increase in the number of dead cells (5,000 total)
in the sample well (Figure 7). Therefore, cells that were initially viable
contribute to the dead cell values after lysis. Because pre- and postlysis signals
are stable after reaching steady-state, the viable cell contribution of any sample
can be determined by a subtractive method:
Signal from Viable Cells = Total Cytotoxicity Signal – Initial Cytotoxic Signal
The Lysis Reagent has the same lytic efficiency as sonication.
Background Luminescence and Inherent Serum Activity
Tissue culture medium supplemented with animal serum may contain detectable
levels of the protease marker used for dead-cell measurement. The level of this
protease activity can vary between different lots of serum. To correct for
variability, background luminescence should be determined using samples that
contain medium plus serum without cells (i.e., the no-cell background control).

Promega Corporation · 2800 Woods Hollow Road · Madison, WI 53711-5399 USA
Toll Free in USA 800-356-9526 · Phone 608-274-4330 · Fax 608-277-2516 · www.promega.com
Printed in USA.
Revised 2/15

Part# TB359
Page 13

5.

General Considerations (continued)
Lysis Reagent
addition

500,000

Total cell number

Luminescence (RLU)

400,000
300,000

Number of dead cells

200,000
100,000
0

0

15

30

Time (minutes)

45

60

6693MA

100% viability control

Figure 7. CytoTox-Glo™ Assay principle. Jurkat cells were washed and adjusted to
50,000 cells/ml in fresh RPMI 1640 medium + 10% FBS. The pool was split: One
fraction was treated by mild sonication to cause cell death; the other was untreated.
Equal volumes of treated and untreated cells were added to the same replicate wells
(100µl final volume, 5,000 cell equivalents/well) to represent a sample population
with 50% viable and 50% dead cells. Viability control wells received 50µl containing
2,500 untreated cells and 50µl of RPMI 1640 + 10% FBS. The AAF-Glo™ reagent was
delivered to sample and control wells at 50µl per well. Luminescence was measured
on a BMG POLARstar luminometer in kinetic mode for 25 minutes to collect the
signal from the control and 50% dead populations. The plate was removed, and
Lysis Reagent was added. After mixing by orbital shaking at 700rpm for 1 minute,
luminescence from the total cytotoxicity was measured in kinetic mode for an
additional 25 minutes.

Assay Controls
In addition to a no-cell background control to establish background
luminescence, we recommend including an untreated-cell control to measure
maximum viability and a positive control to measure maximum cytotoxicity in
the experimental design. The maximum viability control is established by adding
the vehicle used to deliver the test compound to test wells. In most cases, this
consists of a buffer system or medium and the equivalent amount of solvent
used to deliver the test compound. Maximum cytotoxicity can be determined
using the Lysis Reagent. See Section 4.A.
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Temperature
The generation of luminogenic product is proportional to the protease activity
of the marker associated with cytotoxicity. The activity of this protease is
influenced by temperature. For best results, we recommend incubating reactions
at a constant temperature to ensure uniformity across the plate. After adding
the CytoTox-Glo™ Cytotoxicity Assay Reagent and mixing briefly, we suggest
one of two methods:
1. Incubate at room temperature in a water-jacketed incubation module
(Me'Cour, etc.).
2. Incubate at room temperature with or without orbital shaking.
Instrumentation
Luminescence mode: Luminescence chemistry does not require an external
light source to generate photons but generally collects unrestricted/unfiltered
light output.
Cytotoxicity Marker Half-Life
The activity of the protease marker released from dead cells has a half-life
estimated to be greater than 10 hours (Figure 6). In situations where cytotoxicity
occurs rapidly such as necrosis and the incubation time is greater than 24 hours,
the degree of cytotoxicity may be underestimated. When using extended
incubation times, adding a lytic detergent such as digitonin may be useful to
determine the total cytotoxicity marker activity remaining (from remaining live
cells).
Luminescent Signal Half-Life
The CytoTox Glo™ Assay chemistry uses a thermostable, recombinant luciferase
to generate a “glow-type” luminescent signal that is proportional to the number
of dead cells in the sample. After a short signal ramping period (0–15 minutes),
the signal reaches a plateau and is relatively stable for a period of approximately
1 hour (Figure 8). Although the signal half-life is greater than 5 hours, we suggest
measuring the luminescent signal at steady-state (15 minutes to 1 hour).
Light Sensitivity
Although the AAF-Glo™ Substrate demonstrates good general photostability,
aminoluciferin can degrade with prolonged exposure to ambient light sources.
We recommend shielding the plates from ambient light at all times.
Cell Culture Medium
The AAF-Glo™ Substrate is introduced into the test well using an optimized
buffer system that mitigates differences in pH from treatment with your test
compound. In addition, the buffer system supports protease activity in a host of
different culture media with varying osmolarities. With the exception of
medium formulations with very high serum content or phenol red indicator, no
substantial performance differences should be observed among media.
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No Viability
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Figure 8. CytoTox-Glo™ Assay signal.
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7.

Related Products

Cell Viability and Cytotoxicity Assays
Product
MultiTox-Glo Multiplex Cytotoxicity Assay
CytoTox-Fluor™ Cytotoxicity Assay
MultiTox-Fluor Multiplex Cytotoxicity Assay
CellTiter-Glo® Luminescent Cell Viability Assay
CellTiter-Fluor™ Viability Assay
CytoTox-ONE™ Homogeneous Membrane
Integrity Assay
CellTiter-Blue® Cell Viability Assay

Size
10ml
10ml
10ml
10ml
10ml

Cat.#
G9270
G9260
G9200
G7570
G6080

1,000–4,000 assays
20ml

G7891
G8080

Size
10ml
10ml
10ml
10ml

Cat.#
G7790
G8091
G8201
G8211

Size
10ml
10ml

Cat.#
E2610
E2510

Size
10ml
10ml
10ml
10ml
10ml
10ml
10ml
10ml
10ml
10ml

Cat.#
G8501
G8350
G8660
G8760
G8860
G1180
G8531
G8641
G8621
G8631

Additional Sizes Available.

Apoptosis Assays
Product
Apo-ONE® Homogeneous Caspase-3/7 Assay
Caspase-Glo® 3/7 Assay
Caspase-Glo® 8 Assay
Caspase-Glo® 9 Assay
Additional Sizes Available.

Reporter Gene Assays
Product
Bright-Glo™ Luciferase Assay System
Steady-Glo® Luciferase Assay System
Additional Sizes Available.

Protease Assays
Product
Calpain-Glo™ Protease Assay
DPPIV-Glo™ Protease Assay
Proteasome-Glo™ Chymotrypsin-Like Cell-Based Assay
Proteasome-Glo™ Trypsin-Like Cell-Based Assay
Proteasome-Glo™ Caspase-Like Cell-Based Assay
Proteasome-Glo™ 3-Substrate Cell-Based Assay
Proteasome-Glo™ 3-Substrate System
Proteasome-Glo™ Caspase-Like Assay
Proteasome-Glo™ Chymotrypsin-Like Assay
Proteasome-Glo™ Trypsin-Like Assay
Additional Sizes Available.
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7.

Related Products (continued)

cAMP Assay
Product
cAMP-Glo™ Assay

Size
300 assays

Cat.#
V1501

Size
50ml
50ml
50ml
50ml
50ml
50ml
50ml
50ml
50ml
10ml
10ml
50ml

Cat.#
V8752
V8762
V8772
V8782
V8792
V8802
V8812
V8892
V8882
V3591
V3601
V1402

Additional Sizes Available.

ADME Assays
Product
P450-Glo™ CYP1A1 Assay
P450-Glo™ CYP1B1 Assay
P450-Glo™ CYP1A2 Assay
P450-Glo™ CYP2C8 Assay
P450-Glo™ CYP2C9 Assay
P450-Glo™ CYP3A4 Assay
P450-Glo™ CYP3A7 Assay
P450-Glo™ CYP2D6 Assay
P450-Glo™ CYP2C19 Assay
Pgp-Glo™ Assay System
Pgp-Glo™ Assay System with P-glycoprotein
MAO-Glo™ Assay
Additional Sizes Available.

8.

Summary of Changes

The following change was made to the 2/15 revision of this document:
1.

The legal disclaimers were updated.

(a) Patent Pending.
(bU.S. Pat. Nos. 6,602,677, 7,241,584 and 8,030,017, European Pat. No. 1131441, Japanese Pat. Nos. 4537573 and 4520084 and

other patents pending.

© 2007–2015 Promega Corporation. All Rights Reserved.
Apo-ONE, Caspase-Glo, CellTiter 96, CellTiter-Blue, CellTiter-Glo and Steady-Glo are registered trademarks of Promega
Corporation. AAF-Glo, Bright-Glo, Calpain-Glo, cAMP-Glo, CellTiter-Fluor, CytoTox-Fluor, CytoTox-Glo, CytoTox-ONE,
DPPIV-Glo, MAO-Glo, P450-Glo, Pgp-Glo, Proteasome-Glo and Ultra-Glo are trademarks of Promega Corporation.
Products may be covered by pending or issued patents or may have certain limitations. Please visit our Web site for more
information.
All prices and specifications are subject to change without prior notice.
Product claims are subject to change. Please contact Promega Technical Services or access the Promega online catalog for the
most up-to-date information on Promega products.

Promega Corporation · 2800 Woods Hollow Road · Madison, WI 53711-5399 USA
Toll Free in USA 800-356-9526 · Phone 608-274-4330 · Fax 608-277-2516 · www.promega.com
Part# TB359
Page 18

Printed in USA.
Revised 2/15

TECHNICAL BULLETIN

CellTiter-Glo® Luminescent
Cell Viability Assay
Instruc ons for Use of Products
G7570, G7571, G7572 and G7573

Revised 12/12
TB288

CellTiter-Glo® Luminescent
Cell Viability Assay
All technical literature is available at: www.promega.com/protocols/
Visit the web site to verify that you are using the most current version of this Technical Bulletin.
E-mail Promega Technical Services if you have questions on use of this system: techserv@promega.com

1. Description......................................................................................................................................... 1
2. Product Components and Storage Conditions ........................................................................................ 5
3. Performing the CellTiter-Glo® Assay ..................................................................................................... 6
3.A. Reagent Preparation ................................................................................................................... 6
3.B. Protocol for the Cell Viability Assay.............................................................................................. 6
3.C. Protocol for Generating an ATP Standard Curve (optional) ............................................................ 7
4. Appendix ............................................................................................................................................ 8
4.A. Overview of the CellTiter-Glo® Assay............................................................................................ 8
4.B. Additional Considerations ........................................................................................................... 9
4.C. References ............................................................................................................................... 11
4.D. Related Products ...................................................................................................................... 12
1.

Description

The CellTiter-Glo® Luminescent Cell Viability Assay(a–e) is a homogeneous method to determine the number of viable
cells in culture based on quantitation of the ATP present, which signals the presence of metabolically active cells. The
CellTiter-Glo® Assay is designed for use with multiwell-plate formats, making it ideal for automated high-throughput
screening (HTS) and cell proliferation and cytotoxicity assays. The homogeneous assay procedure (Figure 1) involves
adding a single reagent (CellTiter-Glo® Reagent) directly to cells cultured in serum-supplemented medium. Cell
washing, removal of medium or multiple pipetting steps are not required.
The homogeneous “add-mix-measure” format results in cell lysis and generation of a luminescent signal proportional
to the amount of ATP present (Figure 2). The amount of ATP is directly proportional to the number of cells present in
culture in agreement with previous reports (1). The CellTiter-Glo® Assay relies on the properties of a proprietary
thermostable luciferase (Ultra-Glo™ Recombinant Luciferase), which generates a stable “glow-type” luminescent
signal and improves performance across a wide range of assay conditions. The luciferase reaction for this assay is
shown in Figure 3. The half-life of the luminescent signal resulting from this reaction is greater than five hours
(Figure 4). This extended half-life eliminates the need for reagent injectors and provides flexibility for continuous or
batch-mode processing of multiple plates. The unique homogeneous format reduces pipetting errors that may be
introduced during the multiple steps required by other ATP-measurement methods.
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1.

Description (continued)

CellTiter-Glo®
Substrate

CellTiter-Glo®
Buffer

CellTiter-Glo®
Reagent

Luminometer

3170MA12_0A

Mix

Figure 1. Flow diagram showing preparation and use of CellTiter-Glo® Reagent.
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System Advantages
•

Homogeneous: “Add-mix-measure” format reduces the number of plate-handling steps to fewer than that
required for similar ATP assays.

•

Fast: Data can be recorded 10 minutes after adding reagent.

•

Sensitive: Measures cells at numbers below the detection limits of standard colorimetric and fluorometric assays.

•

Flexible: Can be used with various multiwell formats. Data can be recorded by luminometer or CCD camera or
imaging device.

•

Robust: Luminescent signal is very stable, with a half-life >5 hours, depending on cell type and culture medium
used.

•

Able to Multiplex: Can be used with reporter gene assays or other cell-based assays from Promega (2,3).
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Figure 2. Cell number correlates with luminescent output. A direct relationship exists between luminescence
measured with the CellTiter-Glo® Assay and the number of cells in culture over three orders of magnitude. Serial
twofold dilutions of HEK293 cells were made in a 96-well plate in DMEM with 10% FBS, and assays were performed
as described in Section 3.B. Luminescence was recorded 10 minutes after reagent addition using a GloMax®-Multi+
Detection System. Values represent the mean ± S.D. of four replicates for each cell number. The luminescent signal
from 50 HEK293 cells is greater than three times the background signal from serum-supplemented medium without
cells. There is a linear relationship (r2 = 0.99) between the luminescent signal and the number of cells from 0 to 50,000
cells per well.
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Description (continued)
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Figure 3. The luciferase reaction. Mono-oxygenation of luciferin is catalyzed by luciferase in the presence of Mg2+,
ATP and molecular oxygen.

Figure 4. Extended luminescent half-life allows high-throughput batch processing. Signal stability is shown
for three common cell lines. HepG2 and BHK-21 cells were grown and assayed in MEM containing 10% FBS, while
CHO-K1 cells were grown and assayed in DME/F-12 containing 10% FBS. CHO-K1, BHK-21 and HepG2 cells, at
25,000 cells per well, were added to a 96-well plate. After an equal volume of CellTiter-Glo® Reagent was added, plates
were shaken and luminescence monitored over time with the plates held at 22°C. The half-lives of the luminescent
signals for the CHO-K1, BHK-21 and HepG2 cells were approximately 5.4, 5.2 and 5.8 hours, respectively.
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2.

Product Components and Storage Conditions

PRODUCT

SIZE

C A T. #

CellTiter-Glo® Luminescent Cell Viability Assay

10ml

G7570

Substrate is suﬃcient for 100 assays at 100µl/assay in 96-well plates or 400 assays at 25µl/assay in 384-well
plates. Includes:
•
•

1 × 10ml CellTiter-Glo® Buﬀer
1 vial CellTiter-Glo® Substrate (lyophilized)

PRODUCT

CellTiter-Glo® Luminescent Cell Viability Assay

SIZE

C A T. #

10 × 10ml

G7571

Each vial of substrate is suﬃcient for 100 assays at 100µl/assay in 96-well plates or 400 assays at 25µl/assay
in 384-well plates (1,000 to 4,000 total assays). Includes:
•
•

10 × 10ml CellTiter-Glo® Buﬀer
10 vials CellTiter-Glo® Substrate (lyophilized)

PRODUCT

CellTiter-Glo® Luminescent Cell Viability Assay

SIZE

C A T. #

100ml

G7572

Substrate is suﬃcient for 1,000 assays at 100µl/assay in 96-well plates or 4,000 assays at 25µl/assay in
384-well plates. Includes:
•
•

1 × 100ml CellTiter-Glo® Buﬀer
1 vial CellTiter-Glo® Substrate (lyophilized)

PRODUCT

CellTiter-Glo® Luminescent Cell Viability Assay

SIZE

C A T. #

10 × 100ml

G7573

Each vial of substrate is suﬃcient for 1,000 assays at 100µl/assay in 96-well plates or 4,000 assays at
25µl/assay in 384-well plates (10,000 to 40,000 total assays). Includes:
• 10 × 100ml CellTiter-Glo® Buﬀer
•
10 vials CellTiter-Glo® Substrate (lyophilized)
Storage Conditions: For long-term storage, store the lyophilized CellTiter-Glo® Substrate and CellTiter-Glo® Buﬀer
at –20°C. For frequent use, the CellTiter-Glo® Buﬀer can be stored at 4°C or room temperature for 48 hours without
loss of activity. See product label for expiration date information. Reconstituted CellTiter-Glo® Reagent (Buﬀer plus
Substrate) can be stored at room temperature for up to 8 hours with <10% loss of activity, at 4°C for 48 hours with
~5% loss of activity, at 4°C for 4 days with ~20% loss of activity or at –20°C for 21 weeks with ~3% loss of activity.
The reagent is stable for up to ten freeze-thaw cycles, with less than 10% loss of activity.
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3.

Performing the CellTiter-Glo® Assay

Materials to Be Supplied by the User
•
opaque-walled multiwell plates adequate for cell culture
•
multichannel pipette or automated pipetting station for reagent delivery
•
device (plate shaker) for mixing multiwell plates
•
luminometer, CCD camera or imaging device capable of reading multiwell plates
•
optional: ATP for use in generating a standard curve (Section 3.C)
3.A. Reagent Preparation
1.

Thaw the CellTiter-Glo® Buﬀer, and equilibrate to room temperature prior to use. For convenience the
CellTiter-Glo® Buﬀer may be thawed and stored at room temperature for up to 48 hours prior to use.

2.

Equilibrate the lyophilized CellTiter-Glo® Substrate to room temperature prior to use.

3.

Transfer the appropriate volume (10ml for Cat.# G7570 and G7571, or 100ml for Cat.# G7572 and G7573) of
CellTiter-Glo® Buﬀer into the amber bottle containing CellTiter-Glo® Substrate to reconstitute the lyophilized
enzyme/substrate mixture. This forms the CellTiter-Glo® Reagent.

4.

Mix by gently vortexing, swirling or inverting the contents to obtain a homogeneous solution. The CellTiter-Glo®
Substrate should go into solution easily in less than 1 minute.

3.B. Protocol for the Cell Viability Assay
We recommend that you perform a titration of your particular cells to determine the optimal number and ensure that
you are working within the linear range of the CellTiter-Glo® Assay. Figure 2 provides an example of such a titration of
HEK293 cells using 0 to 50,000 cells per well in a 96-well format.
1.

!

Prepare opaque-walled multiwell plates with mammalian cells in culture medium, 100µl per well for 96-well
plates or 25µl per well for 384-well plates.
Multiwell plates must be compatible with the luminometer used.

2.

Prepare control wells containing medium without cells to obtain a value for background luminescence.

3.

Add the test compound to experimental wells, and incubate according to culture protocol.

4.

Equilibrate the plate and its contents at room temperature for approximately 30 minutes.
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5.

Add a volume of CellTiter-Glo® Reagent equal to the volume of cell culture medium present in each well (e.g.,
add 100µl of reagent to 100µl of medium containing cells for a 96-well plate, or add 25µl of reagent to 25µl of
medium containing cells for a 384-well plate).

6.

Mix contents for 2 minutes on an orbital shaker to induce cell lysis.

7.

Allow the plate to incubate at room temperature for 10 minutes to stabilize luminescent signal.
Note: Uneven luminescent signal within standard plates can be caused by temperature gradients, uneven
seeding of cells or edge eﬀects in multiwell plates.

8.

Record luminescence.
Note: Instrument settings depend on the manufacturer. An integration time of 0.25–1 second per well should
serve as a guideline.

3.C. Protocol for Generating an ATP Standard Curve (optional)
It is a good practice to generate a standard curve using the same plate on which samples are assayed. We recommend
ATP disodium salt (Cat.# P1132, Sigma Cat.# A7699 or GE Healthcare Cat.# 27-1006). The ATP standard curve
should be generated immediately prior to adding the CellTiter-Glo® Reagent because endogenous ATPase enzymes
found in sera may reduce ATP levels.
1.

Prepare 1µM ATP in culture medium (100µl of 1µM ATP solution contains 10–10 moles ATP).

2.

Prepare serial tenfold dilutions of ATP in culture medium (1µM to 10nM; 100µl contains 10–10 to 10–12 moles
of ATP).

3.

Prepare a multiwell plate with varying concentrations of ATP standard in 100µl medium
(25µl for a 384-well plate).

4.

Add a volume of CellTiter-Glo® Reagent equal to the volume of ATP standard present in each well.

5.

Mix contents for 2 minutes on an orbital shaker.

6.

Allow the plate to incubate at room temperature for 10 minutes to stabilize the luminescent signal.

7.

Record luminescence.
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4.

Appendix

4.A. Overview of the CellTiter-Glo® Assay
The assay system uses the properties of a proprietary thermostable luciferase to enable reaction conditions that
generate a stable “glow-type” luminescent signal while simultaneously inhibiting endogenous enzymes released during
cell lysis (e.g., ATPases). Release of ATPases will interfere with accurate ATP measurement. Historically, firefly
luciferase purified from Photinus pyralis (LucPpy) has been used in reagents for ATP assays (1,4–7). However, it
has only moderate stability in vitro and is sensitive to its chemical environment, including factors such as pH and
detergents, limiting its usefulness for developing a robust homogeneous ATP assay. Promega has successfully
developed a stable form of luciferase based on the gene from another firefly, Photuris pennsylvanica (LucPpe2), using
an approach to select characteristics that improve performance in ATP assays. The unique characteristics of this mutant
(LucPpe2m) enabled design of a homogeneous single-reagent-addition approach to perform ATP assays with cultured
cells. Properties of the CellTiter-Glo® Reagent overcome the problems caused by factors, such as ATPases, that
interfere with ATP measurement in cell extracts. The reagent is physically robust and provides a sensitive and stable
luminescent output.
Sensitivity and Linearity: The ATP-based detection of cells is more sensitive than other methods (8–10). In
experiments performed by Promega scientists, the luminescent signal from 50 HEK293 cells is greater than three
standard deviations above the background signal from serum-supplemented medium without cells. There is a linear
relationship (r2 = 0.99) between the luminescent signal and the number of cells from 0 to 50,000 cells per well in the
96-well format. The luminescence values in Figure 2 were recorded after 10 minutes of incubation at room temperature
to stabilize the luminescent signal as described in Section 3.B. Incubation of the same 96-well plate used in the
experiment shown in Figure 2 for 360 minutes at room temperature had little eﬀect on the relationship between
luminescent signal and number of cells (r2 = 0.99).
Speed: The homogeneous procedure to measure ATP using the CellTiter-Glo® Assay is quicker than other ATP assay
methods that require multiple steps to extract ATP and measure luminescence. The CellTiter-Glo® Assay also is faster
than other commonly used methods to measure the number of viable cells (such as MTT, alamarBlue® or Calcein-AM)
that require prolonged incubation steps to enable the cells’ metabolic machinery to convert indicator molecules into a
detectable signal.
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4.B. Additional Considerations
Temperature: The intensity and decay rate of the luminescent signal from the CellTiter-Glo® Assay depends on the
luciferase reaction rate. Environmental factors that aﬀect the luciferase reaction rate will change the intensity and
stability of the luminescent signal. Temperature is one factor that aﬀects the rate of this enzymatic assay and thus the
light output. For consistent results, equilibrate assay plates to a constant temperature before performing the assay.
Transferring eukaryotic cells from 37°C to room temperature has little eﬀect on ATP content (5). We have demonstrated that removing cultured cells from a 37°C incubator and allowing them to equilibrate to 22°C for 1–2 hours had
little eﬀect on ATP content. For batch-mode processing of multiple assay plates, take precautions to ensure complete
temperature equilibration. Plates removed from a 37°C incubator and placed in tall stacks at room temperature will
require longer equilibration than plates arranged in a single layer. Insuﬃcient equilibration may result in a temperature
gradient eﬀect between wells in the center and at the edge of the plates. The temperature gradient pattern also may
depend on the position of the plate in the stack.
Chemicals: The chemical environment of the luciferase reaction aﬀects the enzymatic rate and thus luminescence
intensity. Diﬀerences in luminescence intensity have been observed using diﬀerent types of culture media and sera. The
presence of phenol red in culture medium should have little impact on luminescence output. Assaying 0.1µM ATP in
RPMI medium without phenol red resulted in ~5% increase in luminescence output (in relative light units [RLU])
compared to assays in RPMI containing the standard concentration of phenol red, whereas assays in RPMI medium
containing twice the normal concentration of phenol red showed a ~2% decrease in luminescence.
Solvents for the various test compounds may interfere with the luciferase reaction and thus the light output from the
assay. Interference with the luciferase reaction can be detected by assaying a parallel set of control wells containing
medium without cells. Dimethylsulfoxide (DMSO), commonly used as a vehicle to solubilize organic chemicals, has
been tested at final concentrations of up to 2% in the assay and only minimally aﬀects light output.
Plate Recommendations: We recommend using standard opaque-walled multiwell plates suitable for luminescence
measurements. Opaque-walled plates with clear bottoms to allow microscopic visualization of cells also may be used;
however, these plates will have diminished signal intensity and greater cross talk between wells. Opaque white tape
may be used to decrease luminescence loss and cross talk.
Cellular ATP Content: Diﬀerent cell types have diﬀerent amounts of ATP, and values reported for the ATP level in
cells vary considerably (1,4,11–13). Factors that aﬀect the ATP content of cells may aﬀect the relationship between cell
number and luminescence. Anchorage-dependent cells that undergo contact inhibition at high densities may show a
change in ATP content per cell at high densities, resulting in a nonlinear relationship between cell number and
luminescence. Factors that aﬀect the cytoplasmic volume or physiology of cells also will aﬀect ATP content. For
example, oxygen depletion is one factor known to cause a rapid decrease in ATP (1).
Mixing: Optimal assay performance is achieved when the CellTiter-Glo® Reagent is mixed completely with the
cultured cells. Suspension cell lines (e.g., Jurkat cells) generally require less mixing to achieve lysis and extract ATP
than adherent cells (e.g., L929 cells). Tests were done to evaluate the eﬀect of shaking the plate after adding the
CellTiter-Glo® Reagent. Suspension cells cultured in multiwell plates showed only minor diﬀerences in light output
whether or not the plates were shaken after adding the CellTiter-Glo® Reagent. Adherent cells are more diﬃcult to lyse
and show a substantial diﬀerence between shaken and nonshaken plates.
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4.B. Additional Considerations (continued)
Several additional parameters related to reagent mixing include the force of delivery of CellTiter-Glo® Reagent, sample
volume and dimensions of the well. All of these factors may aﬀect assay performance. The degree of reagent mixing
required may be aﬀected by the method used to add the CellTiter-Glo® Reagent to the assay plates. Automated
pipetting devices using a greater or lesser force of fluid delivery may aﬀect the degree of subsequent mixing required.
Complete reagent mixing in 96-well plates should be achieved using orbital plate shaking devices built into many
luminometers and the recommended 2-minute shaking time. Special electromagnetic shaking devices that use a radius
smaller than the well diameter may be required to eﬃciently mix contents of 384-well plates. The depth of medium and
geometry of the multiwell plates may have an eﬀect on mixing eﬃciency. We recommend that you take these factors
into consideration when performing the assay and empirically determine whether a mixing step is necessary for the
individual application.
Luminometers
For highly sensitive luminometric assays, the luminometer model and settings greatly aﬀect the quality of data
obtained. Luminometers from diﬀerent manufacturers will vary in sensitivities and dynamic ranges. We recommend
the GloMax® products because these instruments do not require gain adjustments to achieve optimal sensitivity and
dynamic range. Additionally, GloMax® instruments are preloaded with Promega protocols for ease of use.
If you are not using a GloMax® luminometer, consult the operating manual for your luminometer to determine the
optimal settings. The limits should be verified on each instrument before analysis of experimental samples. The assay
should be linear in some portion of the detection range of the instrument used. For an individual luminometer there
may be diﬀerent gain settings. We recommend that you optimize the gain settings.
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4.D. Related Products
Cell Proliferation Products
Product

Size

Cat.#

ApoLive-Glo™ Multiplex Assay

10ml

G6410

ApoTox-Glo™ Triplex Assay

10ml

G6320

CellTiter-Fluor™ Cell Viability Assay (fluorescent)

10ml

G6080

20ml

G8080

200 assays

G3582

CellTiter-Blue® Cell Viability Assay (resazurin)
CellTiter 96® AQueous One Solution Cell Proliferation Assay (MTS, colorimetric)
CellTiter 96 AQueous Non-Radioactive Cell Proliferation Assay (MTS, colorimetric)
®

CellTiter 96® AQueous MTS Reagent Powder
CellTiter 96® Non-Radioactive Cell Proliferation Assay (MTT, colorimetric)

1,000 assays

G5421

1g

G1111

1,000 assays

G4000

Size

Cat.#

Additional sizes available.

Cytotoxicity Assays
Product
CytoTox-Glo™ Cytotoxicity Assay (luminescent)*

10ml

G9290

Mitochondrial ToxGlo™ Assay*

10ml

G8000

MultiTox-Glo Multiplex Cytotoxicity Assay (luminescent, fluorescent)*

10ml

G9270

MultiTox-Fluor Multiplex Cytotoxicity Assay (fluorescent)*

10ml

G9200

10ml

G9260

200–800 assays

G7890

CytoTox-Fluor™ Cytotoxicity Assay (fluorescent)*
CytoTox-ONE™ Homogeneous Membrane Integrity Assay (LDH, fluorometric)*
CytoTox-ONE™ Homogeneous Membrane Integrity Assay, HTP
CytoTox 96® Non-Radioactive Cytotoxicity Assay (LDH, colorimetric)*
GSH-Glo™ Glutathione Assay
GSH/GSSG-Glo™ Assay

1,000–4,000 assays

G7892

1,000 assays

G1780

10ml

V6911

50ml

V6912

10ml

V6611

50ml

V6612

*Additional sizes available.
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Luminometers
Product
GloMax®-Multi+ Detection System with Instinct™ Software:
Base Instrument with Shaking

Size

Cat.#

1 each

E8032

GloMax -Multi+ Detection System with Instinct™ Software:
Base Instrument with Heating and Shaking

1 each

E9032

GloMax®-Multi+ Luminescence Module

1 each

E8041

Size

Cat.#

Caspase-Glo 2 Assay*

10ml

G0940

Caspase-Glo® 6 Assay*

10ml

G0970

®

Apoptosis Products
Product
®

Caspase-Glo 3/7 Assay*

2.5ml

G8090

Caspase-Glo® 8 Assay*

2.5ml

G8200

Caspase-Glo® 9 Assay*

2.5ml

G8210

1ml

G7792

DeadEnd™ Fluorometric TUNEL System

60 reactions

G3250

DeadEnd™ Colorimetric TUNEL System

20 reactions

G7360

Anti-ACTIVE Caspase-3 pAb

50µl

G7481

Anti-PARP p85 Fragment pAb

50µl

G7341

Anti-pS473 Akt pAb

40µl

G7441

Caspase Inhibitor Z-VAD-FMK, 20mM

50µl

G7231

125µl

G7232

®

Apo-ONE® Homogeneous Caspase-3/7 Assay

®

*Additional sizes available.
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U.S. Pat. Nos. 6,602,677 and 7,241,584, European Pat. No. 1131441, Japanese Pat. Nos. 4537573 and 4520084 and other patents pending.

(b)
(c)

U.S. Pat. No. 7,741,067, Japanese Pat. No. 4485470 and other patents pending.

U.S. Pat. No. 7,700,310, European Pat. No. 1546374 and other patents pending.

(d)

U.S. Pat. Nos 7,083,911, 7,452,663 and 7,732,128, European Pat. No. 1383914 and Japanese Pat. Nos. 4125600 and 4275715.

(e)

The method of recombinant expression of Coleoptera luciferase is covered by U.S. Pat. Nos. 5,583,024, 5,674,713 and 5,700,673.
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